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Summary 
Background: Cardiac surgery-associated acute kidney
injury (CSA-AKI) frequently occurs in patients assessed as
low-risk for developing CSA-AKI. Neutrophil Gelatinase-
Associated Lipocalin (NGAL), Kidney Injury Molecule-1
(KIM-1) and lactate are promising biomarkers of CSA-AKI
but have not yet been explored in low-risk patients. 
Aim: To evaluate urinary NGAL (uNGAL), KIM-1 and lac-
tate as biomarkers of CSA-AKI in patients with low-risk for
developing CSA-AKI. 
Methods: This prospective, observational study included
100 adult elective cardiac surgery patients assessed as low-
risk for developing CSA-AKI. UNGAL, KIM-1 and lactate
were measured preoperatively, at the end of cardiopul-
monary bypass (CPB) and 3, 12, 24 and 48 h later. 
Results: Fifteen patients developed CSA-AKI. Patients with
CSA-AKI had significantly higher lactate but similar uNGAL
and KIM-1 levels compared to patients without CSA-AKI.
Unlike uNGAL and KIM-1, postoperative lactate was good
biomarker of CSA-AKI with the highest odds ratio (OR) 2.7
[1.4–4.9] 24 h after CPB. Peak lactate concentration ≥ 4
Kratak sadr`aj
Uvod: Akutno o{te}enje bubrega nakon kardiohirur{kih pro-
cedura (KH-AOB) nastaje ~esto i kod bolesnika koji su oce -
njeni kao niskorizi~ni za nastanak KH-AOB. Neutrofilna
`elatinaza udru`ena sa lipokalinom (NGAL), bubre`ni {tetni
molekul-1 (KIM-1) i laktat su novi biomarkeri KH-AOB ali do
sada nisu ispitivani kod niskorizi~nih bolesnika. 
Cilj: Ispitati urinarni NGAL (uNGAL), KIM-1 i laktat kao bio-
markere KH-AOB kod bolesnika koji su ocenjeni kao nisko-
rizi~ni za nastanak KH-AOB. 
Metode: Ovom prospektivnom opservacionom studijom obu -
hva}eno je 100 odraslih elektivnih kardiohirur{kih bolesnika
koji su ocenjeni kao niskorizi~ni za razvoj KH-AOB. UNGAL,
KIM-1 i laktat su odre|ivani preoperativno, na kraju kardio -
pulmonalnog bajpasa (KPB) kao i 3, 12, 24 i 48 sati kasnije. 
Rezultati: KH-AOB se razvilo kod 15 bolesnika. Bolesnici sa
KH-AOB su imali zna~ajno vi{e vrednosti lakatata ali sli~ne
vrednosti uNGAL i KIM-1 u pore|enju sa bolesnicima bez
KH-AOB. Za razliku od uNGAL i KIM-1, vrednost lakatata
posle operacije se pokazala kao pouzdan biomarker KH-AOB
sa najvi{im OR 2.7 [1,4–4,9] 24 sata nakon zavr{etka KPB.
List of abbreviations: BMI, Body mass index; CABG, Coronary
artery bypass graft; CPB, Cardiopulmonary bypass; CSA-AKI,
Cardiac surgery-associated cute kidney injury; KIM-1, Kidney
Injury Molecule-1; uNGAL, Urinary Neutrophil Gelatinase-
Associated Lipocalin.
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Introduction
Cardiac surgery carries a greater risk for periop-
erative acute kidney injury (AKI) than any other type
of surgery (1). Cardiac surgery-associated AKI (CSA-
AKI) occurs in approximately 22% of cardiac surgery
patients and is linked to a 5-fold increase in mortality
(2–4). Given the limited prevention and treatment
strategies, recognition of patients at risk for develop-
ment of CSA-AKI is of paramount importance. Risk
assessment has, so far, been restricted to risk scores,
and, arguably, novel biomarkers of AKI. 
The best validated risk scores (5–7) are focused
on predicting severe CSA-AKI requiring dialysis
although mild CSA-AKI is far more likely to occur (3).
The only scoring system designed to predict all stage
CSA-AKI is Leicester Cardiac Surgery Research AKI
Risk Score (8) but it still needs an external validation.
It is very important to acknowledge that CSA-AKI
could also occur in patients that are assessed as low-
risk by available scores. 
Novel biomarkers such as Neutrophil Gela ti -
nase-Associated Lipocalin (NGAL) and Kidney Injury
Molecule-1 (KIM-1) have been studied as potential
biomarkers of CSA-AKI with conflicting results (9,
10). High costs, absence of clear recommendations
as well as difficult interpretation are preventing their
routine use.
Lactate is routinely measured biomarker of tis-
sue hypoperfusion. Hyperlactatemia is common in
cardiac surgery especially if cardiopulmonary bypass
(CPB) is employed (11). Its association with increased
morbidity and mortality is well known (12–15) but
only few recent studies suggested that it might be
linked to development of CSA-AKI (13, 14, 16, 17).
We aimed to evaluate urinary NGAL (uNGAL),
KIM-1 and lactate concentrations as biomarkers of
CSA-AKI in patients undergoing elective cardiac sur-
gery that are assessed as low-risk for development of
CSA-AKI. 
Materials and Methods
This prospective observational study was con-
ducted at the tertiary level adult cardiac surgery
university hospital. The study was approved by the
institutional Ethical Committee and performed in
conformance with the Declaration of Helsinki ethical
guidelines. All patients included in this study signed
an informed consent form.
Patients
A total of 100 adult consecutive consenting
patients fulfilling study criteria were recruited. In -
clusion criteria were age ≥ 18 years, elective cardiac
surgery with cardiopulmonary CPB including coro-
nary artery bypass grafting (CABG), valve surgery or
combined CABG and valve surgery, normal preoper-
ative kidney function and low risk for developing CSA-
AKI. Exclusion criteria were age < 18 years, emer-
gency or redo surgery, preoperative AKI or chronic
kidney disease and medium or high risk for develop-
ing of CSA-AKI. Kidney function was considered nor-
mal if eGFR estimated by Modification of Diet in
Renal Disease (MDRD) study equation (18) was > 60
ml/min per 1.73m2 (19). Risk for developing of CSA-
AKI was assessed according to Cleveland Clinic Score
(5). Patients with Cleveland Clinic Score ≤ 5 are con-
sidered to be at low risk for developing CSA-AKI.
CSA-AKI was diagnosed according to Kidney Disease:
Improving Global Outcomes (KDIGO) criteria (20).
Rapid reversal CSA-AKI was defined by an episode of
AKI that lasts ≤ 48 h or less and acute kidney disease
(AKD) by duration of AKI ≥ 7 days (21). All patients
received routine perioperative care.
Age, gender, type of surgery, duration of CPB,
duration of aortic cross-clamping, intraoperative
blood loss and intraoperative blood transfusion were
recorded. Body mass index (BMI) was calculated
based on anthropometric evaluation (weight, height).
Leicester Cardiac Surgery Research AKI Risk Score in
which percent value presents probability for CSA-AKI
development was also calculated (8).
Samples
Arterial blood and urine samples were collected
simultaneously at predetermined time-points: preop-
eratively (before the induction of anaesthesia), imme-
diately after the end of CPB and 3, 12, 24 and 48
hours after the end of CPB. Lactate levels were meas-
mmol/L carried dramatically higher risk for developing
CSA-AKI (OR 6.3 [1.9–20.5]). 
Conclusions: Unlike uNGAL and KIM-1, postoperative lac-
tate was significant independent predictor of CSA-AKI with
the highest odds ratio 24 h after CPB.
Keywords: acute kidney injury, cardiac surgery, Kidney
Injury Molecule-1, lactate, Neutrophil Gelatinase-Asso -
ciated Lipocalin
Vrednosti lakatata ≥ 4 mmol/L su bile povezane sa dra-
mati~no povi{enim rizikom za nastanak KH-AOB (OR 6,3
[1,9–20,5]). 
Zaklju~ak: Za razliku od uNGAL i KIM-1, vrednosti lakata
posle operacije su bile zna~ajan nezavisni prediktor razvoja
KH-AOB sa najboljom prediktivnom vredno{}u 24 sata
nakon zavr{etka KPB.
Klju~ne re~i: akutno o{te}enje bubrega, kardiohirurgija,
bubre`ni {tetni molekul-1, laktat, neutrofilna `elatinaza
udru`ena sa lipokalinom
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ured immediately after collection using blood gas
analyzer Gem Premier 3000, Instrumentation Labo -
ratory, Milano, Italy. Serum creatinine levels were
measured on the day of collection employing routine
laboratory method (AU680, Beckman Coulter, USA).
Urine samples were centrifuged and stored at -80C
until further analysis. Urine NGAL and KIM-1 levels
were measured using Enzyme-linked Immunosorbent
Assay (ELISA) method (ABBOTT Diagnostics, IL, USA
and R&D Systems Inc, MN, USA, respectively). 
Statistical analysis
Statistical analysis was performed in SPSS
Statistics Version 25 software (SPSS Inc., Chicago, IL,
USA). The normality of data was assessed with
Kolmogorov-Smirnov test. The data are presented as
median and 25th to 75th quartile or frequencies. The
differences between the groups were compared using
the Mann-Whitney U or Chi square test, where appro-
priate. The within-group variations were analyzed
using the Friedman’s test. A univariate binary logistic
regression analysis was employed to test possible pre-
dictors of CSA-AKI. The significance level for all sta-
tistical tests was set at 0.05.
Results
In our study, 15 out of 100 low-risk cardiac sur-
gery patients developed CSA-AKI. Twelve of CSA-AKI
patients had rapid reversal AKI (stage 1 according to
KDIGO definition) and 3 had AKD (stage 2 according
to KDIGO definition).
Baseline characteristics of the patient groups are
shown in Table I. Statistically significant difference
between patients with and without CSA-AKI in age,
gender, BMI, type of surgery, intraoperative blood loss
and transfusion was not found. As expected from the
study design, patients with and without CSA-AKI had
similar Cleveland Clinic Scores but patients with CSA-
AKI had significantly higher risk for developing CSA-
Table I Comparison of the baseline characteristics of the patients with and without CSA-AKI. 
Overall (n = 100) Without CSA-AKI (n = 85)
With CSA-AKI 
(n = 15) p
Age (years) 63.0 [56.25 – 69.0] 63.0 [57.0 – 68.5] 68.0 [60.0 – 73.0] 0.087
Gender (male/female) 77 / 23 66 / 19 11 / 4 0.714
BMI (kg/m2) 27.5 [25.4 – 29.4] 27.3 [25.4 – 29.4] 28.1 [26.0 – 29.3] 0.612
Surgery (valve/CABG/valve + CABG) 21 / 75 / 4 18 /65 /2 3 / 10 / 2 0.134
Duration of CPB (min) 80.0 [64.0 – 97.7] 75.0 [59.5 – 93.0] 101.0 [74.0 – 110.0] 0.012
Duration of aortic cross-clamping (min) 44.5 [30.0 – 60.0] 40 [29.5 – 52.0] 55.0 [39.0 – 71.0] 0.024
Intraoperative blood loss (mL) 1200 [1000 – 1575] 1200 [1000 – 1500] 1400 [1200 – 2000] 0.052
Intraoperative transfusion (mL) 470 [415 – 590] 450 [405 – 565] 576 [430 – 714] 0.082
Hospitalisation (days) 6 [5 – 7] 6 [6 – 7] 7 [6 – 12] 0.017
Cleveland Clinic Score (0 /1 / 2) 39 / 22 / 19 35 /17 /17 4 / 4 / 3 0.514
Leicester Cardiac Surgery Research 
AKI Risk Score (%) 11.51 [8.44 – 15.96] 11.41 [7.41 – 15.23] 15.17 [11.24 – 19.10] 0.018
Baseline creatinine (mmol/L) 74.0 [65.0 – 83.0] 71.0 [64.5 – 80.5] 89.0 [70.0 – 96.0] 0.025
Baseline eGFR (mL/min/1.73 m2) 93.3 [81.3 – 109.8] 95.6 [85.1 – 110.2] 76.4 [64.5 – 90.5] 0.002
Lactate (mmol/L) 1.30 [1.00 – 1.70] 1.3 [1.0 – 1.6] 1.2 [0.9 – 1.8] 0.656
uNGAL (ng/mL) 3.12 [0.39 – 11.78] 3.52 [0.51 – 12.36] 2.36 [0.25 – 6.02] 0.457
KIM-1 (pg/mL) 382.0 [123.5 – 936.0] 437.5 [136.0 – 946.2] 256.5 [86.0 – 760.5] 0.231
Data are presented as median and interquartile range or frequencies. Mann-Whitney U test, Chi-squire test. CSA-AKI – Cardiac
surgery-associated cute kidney injury; BMI – Body mass index; eGFR – Estimated glomerular filtration rate; uNGAL – Urinary
Neutrophil Gelatinase-Associated Lipocalin; KIM-1 – Kidney Injury Molecule-1; CABG – Coronary artery bypass graft; CPB –
Cardiopulmonary bypass.
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Figure 1 Serial (A) lactate, (B) uNGAL and (C) KIM-1 measurements in patients with and without CSA-AKI. 
Data are presented as median and 95% C.I. *Statistically significant difference (p < 0.05) between patients with and without CSA-
AKI at specified time point, Mann-Whitney U test. CSA-AKI – Cardiac surgery-associated acute kidney injury; uNGAL – Urinary
Neutrophil Gelatinase-Associated Lipocalin; KIM-1 – Kidney Injury Molecule-1; CPB – Cardiopulmonary bypass. 
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AKI according to Leicester Cardiac Surgery Research
AKI Risk Score. Although only patients with normal
kidney function were included, patients that devel-
oped CSA-AKI had significantly higher creatinine lev-
els but similar uNGAL and KIM-1 levels compared to
patients without CSA-AKI. CSA-AKI patients also had
longer hospitalization, CPB and aortic cross-clamping
duration. 
Figure 1 depicts serial measurements of lactate
(A), urinary NGAL (B) and KIM-1 (C) in patients with
and without CSA-AKI. After the end of CPB, a signif-
icant increase in concentrations of all three biomark-
ers was noted (p < 0.05 for all timepoints, except for
lactate at 48 h and uNGAL after completion of CPB).
Compared to patients without CSA-AKI, patients with
CSA-AKI had significantly higher lactate levels at all
Odds Ratio [95% C.I.] p
Creatinine (baseline) 1.056 [0.1.013 – 0.101] 0.009
eGFR (baseline) 0.947 [0.910 – 0.984] 0.006
Cleveland Clinic Score 1.164 [0.600 – 2.258] 0.653
Leicester Cardiac Surgery Research AKI Risk Score 1.047 [0.986 – 1.113] 0.135
Duration of CPB 1.016 [1.000 – 1.032] 0.048
Duration of aortic cross-clamping 1.022 [1.002 – 1.043] 0.030
Lactate (baseline) 0.664 [0.204 – 2.159] 0.496
Lactate (CPB) 1.540 [0.831 – 2.852] 0.170
Lactate (3 h) 1.410 [1.022 – 1.944] 0.036
Lactate (12 h) 1.470 [1.007 – 2.146] 0.046
Lactate (24 h) 2.721 [1.485 – 4.986] 0.001
Lactate (48 h) 2.436 [1.227 – 4.837] 0.011
 Lactate (CPB – baseline) 1.936 [0.981 – 3.821] 0.057
 Lactate (3h – baseline) 1.443 [1.034 – 2.015] 0.031
 Lactate (12 h – baseline) 1.501 [1.026 – 2.195] 0.036
 Lactate (24 h – baseline) 2.569 [1.460 – 4.546] 0.001
 Lactate (48 h – baseline) 2.031 [1.109 – 3.719] 0.022
 Lactate (3h – CPB) 1.503 [1.013 – 2.230] 0.043
 Lactate (12 h – CPB) 1.457 [0.930 – 2.283] 0.100
 Lactate (24 h – CPB) 2.173 [1.224 – 3.585] 0.008
 Lactate (48 h – CPB) 1.369 [0.773 – 2.422] 0.281
 Lactate (12 h – 3h) 0.891 [0.604 – 1.313] 0.559
 Lactate (24 h – 3h) 1.003 [0.683 – 1.475] 0.986
 Lactate (48 h – 3h) 0.861 [0.627 – 1.181] 0.352
 Lactate (24 h – 12h) 1.310 [0.725 – 2.368] 0.371
 Lactate (48 h – 12 h) 0.890 [0.598 – 1.325] 0.566
 Lactate (48 h – 24 h) 0.596 [0.331 – 1.074] 0.085
Peak lactate 1.067 [0.939 – 1.212] 0.009
Peak lactate ≥ 4 mmol/L 6.330 [1.957 – 20.472] 0.001
Table II A univariate binary logistic regression for prediction of CSA-AKI.
Data are presented as odds ratio and 95% C.I. Univariate binary logistic regression. CSA-AKI – Cardiac surgery-associated
acute kidney injury; eGFR – Estimated glomerular filtration rate; CPB – Cardiopulmonary bypass.
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time point except at the CPB end. A significant differ-
ence in uNGAL and KIM-1 levels between patients
with and without CSA-AKI was not found except for
uNGAL 3 h after CPB. 
A univariate binary logistic regression was per-
formed in order to identify independent predictors of
CSA-AKI (Table II). As expected, absolute lactate lev-
els at 3, 12, 24 and 48 h after the end of CPB were
independent predictors of CSA-AKI with highest odds
ratio of 2.72 for lactate levels at 24 h after the end of
CPB. Interestingly, the differences in lactate concen-
trations between various time points as well as peak
lactate concentration had lower prediction value then
the absolute lactate concentration. However, peak
lactate ≥ 4 mmol/L was associated with 6.33 times
higher probability for developing CSA-AKI. Baseline
creatinine and eGFR as well as duration of CPB and
aortic cross-clamping were also independent predic-
tors of CSA-AKI.
Discussion
Most of the research on prediction of CSA-AKI is
focused on identifying high-risk patients. However,
CSA-AKI also occurs in patients that are classified as
low-risk so it is reasonable to assume that certain risk
factors are missed by available risk scores. To identify
low-risk patients we used Cleveland Clinic Score.
Cleveland Clinic Score is best validated but, effectively,
predicts only severe CSA-AKI that requires dialysis (5).
On the other hand, Leicester Cardiac Surgery Research
Acute Kidney Injury Risk Score predicts any stage CSA-
AKI but has debatable application outside UK health-
care system (8). It is therefore not surprising that our
patients with CSA-AKI had similar both Cleveland Clinic
scores to patients without CSA-AKI (Table I).
As expected, a significant increase of uNGAL
and KIM-1 levels after CPB was observed (Figure 1B
and 1C). An increase in uNGAL levels after CPB was
already demonstrated in patients without CSA-AKI
(22, 23) and could be a consequence of systemic
inflammation caused by CPB. A significant difference
in either uNGAL or KIM-1 levels between patients
with and without CSA-AKI was not found which
implies that both biomarkers have poor diagnostic
and predictive value as previously reported (9, 10,
24–27). Bulluck at al. (28) demonstarted that pre-
existing chronic kidney disease (CKD) could also alter
NGAL and KIM-1 levels and, consequently, affect
their levels during and after surgery. Patients with pre-
existing CKD were excluded from our study.
In our study lactate concentrations significantly
increased after the end of CPB and were significantly
higher in patients with CSA-AKI (Figure 1A). Con -
sequently, postoperative lactate was good predictor of
CSA-AKI with the highest OR 2.7 for levels at 24 h
after the end of CPB, close to previously reported
(13). To our surprise, the differences in lactate con-
centrations between various time points had lower
prediction value then the absolute lactate concen -
tration (Table II). Mak et al. (13) found that persistent
hyperlactatemia is more important determinant of
post operative outcome than the absolute lactate con -
 centration but their study included patients at high
risk for developing CSA-AKI and only those with
lactate ≥ 3 mmol/L. According to our results (Table
II), low-risk patients with peak lactate concentration ≥
4 mmol/L were 6.3 times more likely to develop CSA-
AKI similarly to findings of Naik et al. (14) although
their study population included high-risk patients.
Normalized lactate load (16), although more compre-
hensive, is labour intensive and, therefore, not very
likely used by clinicians. 
This study has numerous limitations including
small number of patients, short observational period,
infrequent sampling etc. Our results need to be con-
firmed by other researches with larger patient
cohorts, patients with high risk for developing CSA-
AKI and also pediatric cardiac surgery patients.
Conclusions
Our results suggest that, as opposed to uNGAL
and KIM-a, absolute lactate levels could serve as reli-
able biomarkers of CSA-AKI even in cardiac surgery
patients with low risk for developing CSA-AKI. Given
the dramatic increase in CSA-AKI risk, a high level of
vigilance for lactate concentrations ≥ 4 mmol/L
should be maintained. Further investigations are
needed to backup these conclusions.
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